Menten AI GTM brain

category

market profile

• text: Peptide macrocycles may address difficult targets beyond conventional small molecules and biologics, but must achieve potency and drug-like properties together.
• text: Menten sells discovery partnerships and cites Bristol Myers Squibb as a pharma partner; evidence remains preclinical.

personas

• title: VP discovery or therapeutic area research
  pains:

  • High-value protein interactions can be difficult for existing modalities to address.
  • Discovery teams need credible experimentally validated leads, not only computational predictions.
• title: Head of peptide chemistry or computational drug design
  pains:

  • Potency, permeability and stability must be optimized simultaneously.
  • Traditional libraries may undersample relevant macrocycle chemical space.
• title: Biopharma business development leader
  pains:

  • Finding a differentiated platform partner requires evidence of fit with a specific target and clear collaboration terms.

icp

• text: Large pharmaceutical companies with challenging discovery targets and external collaboration budgets, including top-10 pharma.
• text: Biotechs developing peptide therapeutics or pursuing protein-protein interactions where conventional modalities fall short.

message pillars

• text: Design macrocycles for complex targets.
• text: Combine physics and generative methods to explore chemical space.
• text: Optimize drug-like properties in the design process.
• text: Demonstrate evidence across discovery stages.

objections

• objection: Can computational designs become viable drugs?
  response: Review target-specific potency, permeability, DMPK and in vivo data; site claims are preclinical, not clinical efficacy.
• objection: Does the platform fit our target and partnership model?
  response: Scope a target-specific technical and commercial diligence conversation, including experimental validation and intellectual property terms.

competitors

• name: Peptilogics
  website: https://peptilogics.com/ai-discovery-platform/
  why: Uses AI for predictive peptide therapeutic design.
• name: Protagonist Therapeutics
  website: https://www.protagonist-inc.com/technology
  why: Develops peptide therapeutics using molecular design and discovery platforms.
• name: PeptiDream
  why: Peptide and macrocycle discovery company competing for drug discovery programs.

influencers

• name: Hans Melo
  url: https://www.linkedin.com/posts/hansmelo_maud-10-generative-ai-platform-for-design-activity-7419454028738330625-dz2i
  why: CEO and co-founder who announced MAUD 1.0.

keywords

• cyclic peptide drug discovery
• AI macrocycle design
• protein protein interaction therapeutics
• oral peptide discovery
• physics based drug design
• cell permeable peptides

voice

• scientific
• ambitious
• partnership-oriented

signals

• text: Pharma company has announced a difficult protein interaction target or peptide modality initiative.
• text: Biotech seeks external discovery partners for oral or cell-permeable peptides.

stack

• Google Cloud Platform
• GitLab
• PostgreSQL
• Python
• TypeScript

hiring

• Senior Cloud and DevOps Engineer

pricing

motion

channels

• LinkedIn
• scientific publications
• industry conferences
• partnership outreach

confidence

Founders

• name: Tamas Gorbe
  title: Founder
  role: Founder
  bio: TechBio startup founder with hands-on operational and finance experience. Working at the intersection of chemistry, biology, and computer science. Passionate about investing and value creation in the Life Science ecosystem. Outside of work, I enjoy several different sports activities, such as scuba diving, surfing, MTB, wakeboarding, and have 10 years of triathlon experience.
• name: Hans Melo
  title: Founder
  role: Founder